Business
NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
Results illustrate how NetraMark’s advanced AI can potentially support precision enrichment strategies in future trialsTORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today announced new findings illustrating the ability of its proprietary explainable AI platform, NetraAI, to uncover
About this update from Netramark Holdings Inc
[{"type":"image","alt":"NetraMark Holdings Inc.","displaySize":"","headline":null,"caption":"NetraMark Holdings Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/192769f9f65e10ea97c7137b2337b7be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cKmM3wfaRebYT3SszZY1sQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/192769f9f65e10ea97c7137b2337b7be","width":300,"height":94}},"lazy":false},{"type":"text","content":"Results illustrate how NetraMark’s advanced AI can potentially support precision enrichment strategies in future trials","length":119,"tagName":"p"},{"type":"text","content":"TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today announced new findings illustrating the ability of its proprietary explainable AI platform, NetraAI, to uncover clinically meaningful responder subgroups within the landmark Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial.","length":514,"tagName":"p"},{"type":"text","content":"The results, were presented in a poster titled, “Decoding Heterogeneity in A4: Explainable ML Identifies Solanezumab-Responsive Subgroups in Preclinical AD,” which highlight how NetraMark’s technology has the potential to reveal therapeutic signals that may be obscured in conventional clinical trial analyses.","length":310,"tagName":"p"},{"type":"text","content":"The poster was presented at the Alzheimer’s Disease & Parkinson’s Diseases (AD/PD) 2026 International Conference, taking place March 17 - 21, 2026, in Copenhagen, Denmark during the poster sessions.","length":202,"tagName":"p"},{"type":"text","content":"Explainable AI Identifies Hidden Treatment Response","length":51,"tagName":"p"},{"type":"text","content":"Using a dynamical-systems-based explainable machine learning approach, NetraAI analyzed multimodal baseline variables including imaging, cognitive assessments, demographics, and biomarkers from participants in the A4 study.","length":223,"tagName":"p"},{"type":"text","content":"Although the original Phase 3 A4 trial showed no statistically significant overall benef...